Page last updated: 2024-12-05

3,3-dimethylbutan-1-ol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,3-dimethylbutan-1-ol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12233
CHEMBL ID25029
SCHEMBL ID13695
MeSH IDM0050689

Synonyms (47)

Synonym
543oyd666t ,
unii-543oyd666t
1-butanol, 3,3-dimethyl-
nsc-54158
3,3-dimethyl-1-butanol
nsc54158
1-butanol,3-dimethyl-
624-95-3
c6h14o
nsc 54158
3,3-dimethylbutan-1-ol
einecs 210-872-6
tert-hexyl alcohol
tert-hexanol
3,3-dimethyl-1-butanol, 98%
CHEMBL25029 ,
neohexanol
D1333
3,3-dimethyl-butan-1-ol
bdbm50026474
A8638
AKOS005254404
33D ,
3,3-dimethylbutanol
26401-20-7
FT-0630014
AM20100528
1-butanol, 3,3-dimethyl
3,3dimethyl-1-butanol
3,3-dimethyl butan-1-ol
SCHEMBL13695
DTXSID3060796
mfcd00002928
J-511080
dimbunol
BBL103889
STL557699
BCP21756
Q25109997
AS-18452
3,3-dimethyl-1-butanol; 3,3-dimethylbutanol; dimbunol; nsc 54158; 1-butanol, 3,3-dimethyl-
EN300-95055
CS-W013693
3,3-dimethyl-1-butanol (liquid)
dmb; neohexanol
3 pound not3-dimethylbutanol
HY-W012977

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Vascular dysfunction: develops progressively with ageing; increases the risk of cardiovascular diseases (CVD); and is characterized by endothelial dysfunction and arterial stiffening, which are primarily mediated by superoxide-driven oxidative stress and consequently reduced nitric oxide (NO) bioavailability and arterial structural changes."( Initiation of 3,3-dimethyl-1-butanol at midlife prevents endothelial dysfunction and attenuates in vivo aortic stiffening with ageing in mice.
Brunt, VE; Casso, AG; Clayton, ZS; Davy, KP; Gioscia-Ryan, RA; Greenberg, NT; Hutton, DA; Neilson, AP; Seals, DR; VanDongen, NS; Ziemba, BP, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
choline degradation III14

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Choline O-acetyltransferase Rattus norvegicus (Norway rat)Ki13,250.00000.00020.00130.0030AID30247; AID30248
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID30247Compound was evaluated for reversible inhibition of hydrolysis acetylcholine by acetylcholinesterase and represented as KI(competitive)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Effects of charge, volume, and surface on binding of inhibitor and substrate moieties to acetylcholinesterase.
AID158688Inhibitory activity against Plasmodium falciparum1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis.
AID30248Compound was evaluated for reversible inhibition of hydrolysis acetylcholine by acetylcholinesterase and represented as KI(noncompetitive)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Effects of charge, volume, and surface on binding of inhibitor and substrate moieties to acetylcholinesterase.
AID30253Compound was evaluated for reversible inhibition of hydrolysis acetylcholine by acetylcholinesterase and represented as Km(app) apparent binding constant1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Effects of charge, volume, and surface on binding of inhibitor and substrate moieties to acetylcholinesterase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (27.78)18.7374
1990's1 (5.56)18.2507
2000's1 (5.56)29.6817
2010's6 (33.33)24.3611
2020's5 (27.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.19 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.46 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]